File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B

TitlePredictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
Authors
Issue Date2002
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2002, v. 36 n. 1, p. 186-194 How to Cite?
AbstractElevated alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatitis B treated with interferon. Predictors of HBeAg loss in patients treated with lamivudine are not known. The objective of this analysis of 4 lamivudine-controlled Phase III trials was to determine patient-dependent or laboratory variables that predict HBeAg loss. Predictors of HBeAg loss in patients treated with interferon, lamivudine plus interferon, or placebo are also described. A total of 805 adults with chronic hepatitis B were treated either with lamivudine (n = 406), matching placebo (n = 196), interferon (n = 68), or the combination of lamivudine plus interferon (n = 135). Demographic and baseline disease characteristics were used in stepwise multivariate analyses to identify features that were predictive of lamivudine-induced HBeAg loss. HBeAg loss correlated with increased pretreatment ALT levels in all groups. The rate of HBeAg loss was highest among patients with pretreatment ALT levels greater than 5 times the upper limit of normal (ULN) and was most pronounced in the lamivudine group (56%). Multivariate modeling indicated that elevated baseline ALT levels (P < .001) and histologic activity index (HAI) score (P < .001) were important predictors of HBeAg loss in response to lamivudine. The effect of pretreatment ALT levels on HBeAg loss was similar for Asians and Caucasians. In conclusion, elevated pretreatment ALT levels and/or active histologic disease were the most important predictors of lamivudine-induced HBeAg loss. Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels.
Persistent Identifierhttp://hdl.handle.net/10722/78567
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPerrillo, RPen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorLiaw, YFen_HK
dc.contributor.authorDienstag, JLen_HK
dc.contributor.authorSchiff, ERen_HK
dc.contributor.authorSchalm, SWen_HK
dc.contributor.authorHeathcote, EJennyen_HK
dc.contributor.authorBrown, NAen_HK
dc.contributor.authorAtkins, Men_HK
dc.contributor.authorWoessner, Men_HK
dc.contributor.authorGardner, SDen_HK
dc.date.accessioned2010-09-06T07:44:18Z-
dc.date.available2010-09-06T07:44:18Z-
dc.date.issued2002en_HK
dc.identifier.citationHepatology, 2002, v. 36 n. 1, p. 186-194en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78567-
dc.description.abstractElevated alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatitis B treated with interferon. Predictors of HBeAg loss in patients treated with lamivudine are not known. The objective of this analysis of 4 lamivudine-controlled Phase III trials was to determine patient-dependent or laboratory variables that predict HBeAg loss. Predictors of HBeAg loss in patients treated with interferon, lamivudine plus interferon, or placebo are also described. A total of 805 adults with chronic hepatitis B were treated either with lamivudine (n = 406), matching placebo (n = 196), interferon (n = 68), or the combination of lamivudine plus interferon (n = 135). Demographic and baseline disease characteristics were used in stepwise multivariate analyses to identify features that were predictive of lamivudine-induced HBeAg loss. HBeAg loss correlated with increased pretreatment ALT levels in all groups. The rate of HBeAg loss was highest among patients with pretreatment ALT levels greater than 5 times the upper limit of normal (ULN) and was most pronounced in the lamivudine group (56%). Multivariate modeling indicated that elevated baseline ALT levels (P < .001) and histologic activity index (HAI) score (P < .001) were important predictors of HBeAg loss in response to lamivudine. The effect of pretreatment ALT levels on HBeAg loss was similar for Asians and Caucasians. In conclusion, elevated pretreatment ALT levels and/or active histologic disease were the most important predictors of lamivudine-induced HBeAg loss. Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshEthnic Groupsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B Antibodies - blooden_HK
dc.subject.meshHepatitis B e Antigens - blood - immunologyen_HK
dc.subject.meshHepatitis B virus - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - therapeutic useen_HK
dc.subject.meshInterferons - therapeutic useen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlacebosen_HK
dc.subject.meshRecombinant Proteinsen_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePredictors of HBeAg loss after lamivudine treatment for chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=36&spage=186&epage=194&date=2002&atitle=Predictors+of+HBeAg+Loss+After+Lamivudine+Treatment+for+Chronic+Hepatitis+Ben_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/jhep.2002.34294en_HK
dc.identifier.pmid12085364-
dc.identifier.scopuseid_2-s2.0-18444367980en_HK
dc.identifier.hkuros80569en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-18444367980&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue1en_HK
dc.identifier.spage186en_HK
dc.identifier.epage194en_HK
dc.identifier.isiWOS:000176534300023-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridPerrillo, RP=7004982642en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridLiaw, YF=7202451038en_HK
dc.identifier.scopusauthoridDienstag, JL=24498972800en_HK
dc.identifier.scopusauthoridSchiff, ER=7102846957en_HK
dc.identifier.scopusauthoridSchalm, SW=7103298140en_HK
dc.identifier.scopusauthoridHeathcote, EJenny=16232754400en_HK
dc.identifier.scopusauthoridBrown, NA=7403548663en_HK
dc.identifier.scopusauthoridAtkins, M=16738020300en_HK
dc.identifier.scopusauthoridWoessner, M=6603331867en_HK
dc.identifier.scopusauthoridGardner, SD=7201943931en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats